VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

Title
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Authors
Keywords
-
Journal
CLINICAL CANCER RESEARCH
Volume 18, Issue 2, Pages 499-509
Publisher
American Association for Cancer Research (AACR)
Online
2011-12-01
DOI
10.1158/1078-0432.ccr-11-1625

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started